Sun Pharma, Lupin & Dr Reddy’s Recall Products in U.S.—Highlighting Quality Risks for Indian Pharma

Three major Indian pharmaceutical firms—

, , and —have initiated voluntary product recalls in the U.S. due to manufacturing and packaging issues. While these are Class II recalls—meaning they pose no serious health risk—they highlight increasing regulatory scrutiny on Indian drugmakers. Sun Pharma recalled 5,448 bottles of Lisdexamfetamine Dimesylate capsules (used for ADHD) due to failure in dissolution tests. Lupin recalled 58,968 bottles of Lisinopril-Hydrochlorothiazide tablets after some bottles were found to contain wrong tablets (Atazanavir-Ritonavir). Dr. Reddy’s recalled 1,476 bottles of Omeprazole capsules after discovering Divalproex Sodium tablets in some containers. All three recalls were classified as Class II by the U.S. FDA—indicating temporary or medically reversible adverse effects are possible, but not likely to cause serious harm. These incidents don’t pose a major threat to consumers, but they underline the urgent need for robust quality control. For Indian pharmaceutical companies—which supply a large portion of generic drugs globally—regulatory compliance is critical for credibility and market access. As Indian firms expand globally, maintaining stringent manufacturing practices and packaging oversight is essential to avoid reputational damage and regulatory penalties. Source: NDTV Profit No Recommendations